Literature DB >> 29339388

Combating Carbapenem-Resistant Acinetobacter baumannii by an Optimized Imipenem-plus-Tobramycin Dosage Regimen: Prospective Validation via Hollow-Fiber Infection and Mathematical Modeling.

Cornelia B Landersdorfer1,2,3, Rajbharan Yadav4, Jürgen B Bulitta5, Kate E Rogers4,2, Tae Hwan Kim6,7, Beom Soo Shin7, John D Boyce8, Roger L Nation4.   

Abstract

We aimed to prospectively validate an optimized combination dosage regimen against a clinical carbapenem-resistant Acinetobacter baumannii (CRAB) isolate (imipenem MIC, 32 mg/liter; tobramycin MIC, 2 mg/liter). Imipenem at constant concentrations (7.6, 13.4, and 23.3 mg/liter, reflecting a range of clearances) was simulated in a 7-day hollow-fiber infection model (inoculum, ∼107.2 CFU/ml) with and without tobramycin (7 mg/kg q24h, 0.5-h infusions). While monotherapies achieved no killing or failed by 24 h, this rationally optimized combination achieved >5 log10 bacterial killing and suppressed resistance.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Acinetobacter baumannii; carbapenem resistance; dynamic hollow-fiber infection model; mathematical modeling; mechanism based; mechanistic; pharmacodynamics; pharmacokinetics; synergy

Mesh：

Substances：

Year:  2018        PMID： 29339388      PMCID： PMC5913956          DOI： 10.1128/AAC.02053-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  42 in total

1.  Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia.

Authors:  M Bernabeu-Wittel; C Pichardo; A García-Curiel; M E Pachón-Ibáñez; J Ibáñez-Martínez; M E Jiménez-Mejías; J Pachón
Journal:  Clin Microbiol Infect       Date:  2005-04       Impact factor: 8.067

2.  TDM-guided therapy with daptomycin and meropenem in a morbidly obese, critically ill patient.

Authors:  Federico Pea; Piergiorgio Cojutti; Rodolfo Sbrojavacca; Barbara Cadeo; Francesco Cristini; Alessandro Bulfoni; Mario Furlanut
Journal:  Ann Pharmacother       Date:  2011-07-12       Impact factor: 3.154

3.  Emergence of carbapenem resistance in Acinetobacter baumannii recovered from blood cultures in Australia.

Authors:  Anton Y Peleg; Clare Franklin; Jan M Bell; Denis W Spelman
Journal:  Infect Control Hosp Epidemiol       Date:  2006-06-20       Impact factor: 3.254

4.  Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.

Authors:  Bala Kishan Gorityala; Goutam Guchhait; Sudeep Goswami; Dinesh M Fernando; Ayush Kumar; George G Zhanel; Frank Schweizer
Journal:  J Med Chem       Date:  2016-08-30       Impact factor: 7.446

5.  Comparative in vitro antimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activities of nine antimicrobial combinations.

Authors:  M B Marques; E S Brookings; S A Moser; P B Sonke; K B Waites
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

6.  Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations.

Authors:  Brian T Tsuji; Jurgen B Bulitta; Tanya Brown; Alan Forrest; Pamela A Kelchlin; Patty N Holden; Charles A Peloquin; Laura Skerlos; Debra Hanna
Journal:  J Antimicrob Chemother       Date:  2012-06-08       Impact factor: 5.790

7.  OmpA is the principal nonspecific slow porin of Acinetobacter baumannii.

Authors:  Etsuko Sugawara; Hiroshi Nikaido
Journal:  J Bacteriol       Date:  2012-05-25       Impact factor: 3.490

Review 8.  Hospital-acquired infections due to gram-negative bacteria.

Authors:  Anton Y Peleg; David C Hooper
Journal:  N Engl J Med       Date:  2010-05-13       Impact factor: 91.245

9.  Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations.

Authors:  Jean-Marie Conil; Bernard Georges; Stéphanie Ruiz; Thomas Rival; Thierry Seguin; Pierre Cougot; Olivier Fourcade; Georges Houin Pharmd; Sylvie Saivin
Journal:  Br J Clin Pharmacol       Date:  2011-01       Impact factor: 4.335

10.  Clinical implications of cefazolin inoculum effect and β-lactamase type on methicillin-susceptible Staphylococcus aureus bacteremia.

Authors:  Shinwon Lee; Ki Tae Kwon; Hye-In Kim; Hyun Ha Chang; Jong-Myung Lee; Pyoeng Gyun Choe; Wan Beom Park; Nam Joong Kim; Myoung-Don Oh; Do Young Song; Shin-Woo Kim
Journal:  Microb Drug Resist       Date:  2014-12       Impact factor: 3.431
View more
  7 in total

1.  Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients.

Authors:  Rajbharan Yadav; Phillip J Bergen; Kate E Rogers; Carl M J Kirkpatrick; Steven C Wallis; Yuling Huang; Jürgen B Bulitta; David L Paterson; Jeffrey Lipman; Roger L Nation; Jason A Roberts; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

Review 2.  Pharmacodynamic Drug-Drug Interactions.

Authors:  Jin Niu; Robert M Straubinger; Donald E Mager
Journal:  Clin Pharmacol Ther       Date:  2019-04-26       Impact factor: 6.875

3.  Using machine learning to optimize antibiotic combinations: dosing strategies for meropenem and polymyxin B against carbapenem-resistant Acinetobacter baumannii.

Authors:  N M Smith; J R Lenhard; K R Boissonneault; C B Landersdorfer; J B Bulitta; P N Holden; A Forrest; R L Nation; J Li; B T Tsuji
Journal:  Clin Microbiol Infect       Date:  2020-02-12       Impact factor: 8.067

Review 4.  Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis.

Authors:  Jürgen B Bulitta; Yuanyuan Jiao; Stefanie K Drescher; Antonio Oliver; Arnold Louie; Bartolome Moya; Xun Tao; Mathias Wittau; Brian T Tsuji; Alexandre P Zavascki; Beom Soo Shin; George L Drusano; Fritz Sörgel; Cornelia B Landersdorfer
Journal:  Clin Pharmacokinet       Date:  2019-02       Impact factor: 6.447

5.  Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients.

Authors:  Vanessa E Rees; Rajbharan Yadav; Kate E Rogers; Jürgen B Bulitta; Veronika Wirth; Antonio Oliver; John D Boyce; Anton Y Peleg; Roger L Nation; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

Review 6.  Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans.

Authors:  Jürgen B Bulitta; William W Hope; Ann E Eakin; Tina Guina; Vincent H Tam; Arnold Louie; George L Drusano; Jennifer L Hoover
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

Review 7.  When One Drug Is Not Enough: Context, Methodology, and Future Prospects in Antibacterial Synergy Testing.

Authors:  Thea Brennan-Krohn; James E Kirby
Journal:  Clin Lab Med       Date:  2019-06-12       Impact factor: 1.935
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.